drugset

drugset / Trial / NCT04743687

Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial

NCT04743687 ↗

Phase 2 Unknown 30 enrolled Peking Union Medical College Hospital

NaSingle-groupOpen-labelTreatment

Summary

To explore the effectiveness and safety of Zanuburutinib in relapsed and refractory idiopathic Multicentric Castleman's disease (iMCD) patients.

Timeline

Start: 2021-01-01
Primary completion: 2025-01-01
Completion: 2025-01-01

Outcome

Missed primary endpoint

paper none of the 5 patients had an overall response by Week 12. PMID 38546960 ↗

Publications

Zhang L, Gao YH, Li SY, Zhao H, Zhang MY, Yu YY, Liu YT, Li J. A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease. Int J Hematol. 2024 Jun;119(6):631-637. doi: 10.1007/s12185-024-03747-7. Epub 2024 Mar 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zanubrutinib	Small molecule	160 mg	Oral

Indications